Shionogi Relinquishes HIV Portfolio; Joins Pfizer, GSK As Shareholders In ViiV
This article was originally published in PharmAsia News
Executive Summary
Shionogi will clear up cash by turning over global rights to its integrase inhibitor portfolio to its joint venture partner in exchange for royalties and equity in ViiV.